Allergy Therapeutics expects full-year revenue in line with expectations

09:54 12/07/2018
StockMarketWire.com - Allergy Therapeutics said Thursday it expected that full-year revenues and expenses would be in-line with market expectations amid 'strong' performance in an 'unusually weak' pollen season.

For the year ended 30 June 2018, reported revenues are expected to come in at £68.3m, up 6.6% from £64.1m the previous year.

The company said it gained a 0.7 market share point within its core markets in Europe.

The cash balance at the end of June 2018 was £15.5m compared with £22.1m the previous year.

The ongoing pipeline trials continued to progress well, and the company remained on track to deliver the results of the pivotal Birch Phase III trial for Europe in the third quarter of 2018.





At 9:54am: (LON:AGY) Allergy Therapeutics PLC share price was 0p at 28.25p


Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
23:08 Royal Mail suffers shareholder revolt as...
source: The Daily Mail
22:51 Boeing gets 528 orders at Farnborough...
source: The Daily Mail
22:51 Sports Direct boss Mike Ashley pays...
source: The Daily Mail
22:51 What's Sir Paul Tucker's beef with FCA...
source: The Daily Mail
22:33 All of Poundworld's 355 stores to close...
source: The Daily Mail
22:18 Charts That Count: Another China Crisis?
source: FT.com
22:09 Trump criticises Federal Reserve’s...
source: FT.com
22:05 DAILY BRIEFING: Boeing gets 528 orders...
source: The Daily Mail
22:05 ALL of Poundworld's 355 stores to close...
source: The Daily Mail
22:04 CITY DIARY: What's ex-deputy Bank...
source: The Daily Mail
[more ...]